Collegium Pharmaceutical, Inc.

NasdaqGS:COLL 株式レポート

時価総額：US$1.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Collegium Pharmaceutical マネジメント

マネジメント 基準チェック /44

Collegium Pharmaceutical'sの CEO はMike Heffernanで、 Jan2002年に任命され、 の在任期間は 22.42年です。 は、会社の株式の0.086%を直接所有しており、その価値は$ 891.72K 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と10.3年です。

主要情報

Mike Heffernan

最高経営責任者

US$330.6k

報酬総額

CEO給与比率n/a
CEO在任期間22.4yrs
CEOの所有権0.09%
経営陣の平均在職期間4.8yrs
取締役会の平均在任期間10.3yrs

経営陣の近況

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Recent updates

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

Collegium Pharmaceutical: Thoughts After Another Strategic Move

Feb 20

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Feb 15
There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Oct 30
We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

CEO報酬分析

Collegium Pharmaceutical の収益と比較して、Mike Heffernan の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

US$93m

Dec 31 2023US$331kn/a

US$48m

Sep 30 2023n/an/a

US$9m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$334kn/a

-US$25m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

US$43m

Dec 31 2021US$353kn/a

US$72m

Sep 30 2021n/an/a

US$104m

Jun 30 2021n/an/a

US$107m

Mar 31 2021n/an/a

US$42m

Dec 31 2020US$304kn/a

US$27m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$198k

Mar 31 2020n/an/a

-US$13m

Dec 31 2019US$251kn/a

-US$23m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$22m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$5mUS$317k

-US$39m

Sep 30 2018n/an/a

-US$66m

Jun 30 2018n/an/a

-US$62m

Mar 31 2018n/an/a

-US$70m

Dec 31 2017US$3mUS$547k

-US$75m

報酬と市場: Mikeの 総報酬 ($USD 330.61K ) は、 US市場 ($USD 3.40M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Mikeの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Mike Heffernan (60 yo)

22.4yrs

在職期間

US$330,614

報酬

Mr. Michael Thomas Heffernan, also known as Mike, B.S. Pharm, R.Ph. serve as Independent Director at K36 Therapeutics, Inc. He serves as Lead Independent Director at Biohaven Ltd. since September 2022.Mr....

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Michael Heffernan
Co-Founder22.4yrsUS$330.61k0.086%
$ 891.7k
Colleen Tupper
Executive VP & CFO3.1yrsUS$2.73m0.060%
$ 627.2k
Shirley Kuhlmann
Executive VP6.3yrsUS$2.87m0.062%
$ 643.5k
Scott Dreyer
Executive VP & Chief Commercial Officer5.9yrsUS$2.61m0%
$ 0
Thomas Smith
Executive VP & Chief Medical Officer2.3yrsUS$2.04m0.028%
$ 293.4k
Christopher James
Vice President of Investor Relationsno dataデータなしデータなし
Bart Dunn
Executive Vice President of Strategy & Corporate Development4.8yrsデータなしデータなし
Scott Sudduth
Head of Technical Operations2.7yrsデータなしデータなし

4.8yrs

平均在職期間

52yo

平均年齢

経験豊富な経営陣: COLLの経営陣は 経験豊富 であると考えられます ( 4.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Michael Heffernan
Co-Founder20.7yrsUS$330.61k0.086%
$ 891.7k
John Freund
Independent Director10.3yrsUS$298.61k0.21%
$ 2.2m
Garen Bohlin
Independent Director9.4yrsUS$299.61k0.0072%
$ 74.8k
Gino Santini
Lead Independent Director11.9yrsUS$322.61k0.078%
$ 809.5k
Bill McCarberg
Scientific Advisorno dataデータなしデータなし
Nathaniel Katz
Scientific Advisorno dataデータなしデータなし
Robert Dworkin
Scientific Advisorno dataデータなしデータなし
Lynn Webster
Scientific Advisorno dataデータなしデータなし
John Fallon
Independent Director8yrsUS$289.61k0.11%
$ 1.2m
Cynthia McCormick
Scientific Advisorno dataデータなしデータなし
Richard Rauck
Scientific Advisorno dataデータなしデータなし
Charles Argoff
Scientific Advisorno dataデータなしデータなし

10.3yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: COLLの 取締役会 は経験豊富で 経験豊富 です ( 10.3年の平均在任期間)。